Risk of Adverse Events in Cancer Patients Receiving Nivolumab With Ipilimumab: A Meta-Analysis

BACKGROUND: Combining two immune checkpoint inhibitors (ICIs) instead of using one can effectively improve the prognosis of advanced malignant tumors. At present, ipilimumab alongside nivolumab is the most widely used combinatorial regimen of ICIs. However, the risk of treatment-related adverse even...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhao, Xin, Gao, Fengwei, Yang, Jie, Fan, Hua, Xie, Qingyun, Jiang, Kangyi, Gong, Jie, Gao, Benjian, Yang, Qian, Lei, Zehua
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9260026/
https://www.ncbi.nlm.nih.gov/pubmed/35814436
http://dx.doi.org/10.3389/fonc.2022.877434

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9260026/
https://www.ncbi.nlm.nih.gov/pubmed/35814436
http://dx.doi.org/10.3389/fonc.2022.877434

Ejemplares similares